NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer. This ...
The article by Di Federico et al titled “Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations” (JCO Precis Oncol ...
The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...
Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...
Morning Overview on MSN
Scientists finally crack why some cancer treatments suddenly stop working
After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results